Testing version — LOERadar is in active testing. Features and data may change.

CARBIDOPA, LEVODOPA AND ENTACAPONE (CARBIDOPA; ENTACAPONE; LEVODOPA) | LOERadar

Viewing data from:

CARBIDOPA, LEVODOPA AND ENTACAPONE

ANDA

CARBIDOPA; ENTACAPONE; LEVODOPA | A203424 | PHARMOBEDIENT CONSULTING LLC

6 strengths0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Orion Corporation v. Mylan Pharmaceuticals Inc. 1:2012cv00523 3 patentsANDA 203424carbidopa, levodopa, and entacapone	D. Del.	2012-04-26	Terminated 2014-03-05	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Products (6)

Sort:

#001 — 12.5MG;200MG;50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 13, 2020

No patent or exclusivity listings for this strength.

#002 — 18.75MG;200MG;75MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 13, 2020

#003 — 25MG;200MG;100MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 13, 2020

#004 — 31.25MG;200MG;125MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 13, 2020

#005 — 37.5MG;200MG;150MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 13, 2020

#006 — 50MG;200MG;200MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 13, 2020